REGENXBIO, Inc. (RGNX)
8.10
-0.26
(-3.11%)
USD |
NASDAQ |
Mar 20, 16:00
8.125
+0.02
(+0.31%)
After-Hours: 20:00
REGENXBIO Research and Development Expense (Quarterly) : 55.74M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Sarepta Therapeutics, Inc. | 319.50M |
| AbbVie, Inc. | 2.579B |
| Krystal Biotech, Inc. | 13.23M |
| Replimune Group, Inc. | 52.87M |
| Ocugen, Inc. | 10.67M |